Bulk sequencing studies on the peripheral blood (PB) of normal individuals with no overt signs of myeloid malignancies have revealed that DNMT3A mutations occur as preleukemic somatic mutations that can be later detected in patients with full-blown AML (5–8). The gene discussed is DNMT3A; the disease is myeloid neoplasm.